Greater Cannabis Company Business Summary

The Greater Cannabis Company, Inc. (GCAN) operates as a clinical-stage biopharmaceutical firm specializing in the development and commercialization of innovative cannabinoid delivery systems and therapeutics. The company’s revenue model is primarily driven by the licensing of its intellectual property (IP) and the clinical validation of its proprietary Eluting Transmucosal Patch (ETP) platform. This technology facilitates the rapid absorption of cannabinoids through the buccal mucosa, bypassing first-pass metabolism to enhance bioavailability and dosing precision for neuropsychiatric conditions such as Autism Spectrum Disorder (ASD), schizophrenia, and Parkinson’s disease. GCAN competes in a specialized niche alongside firms like Bright Green (BGXX), Petros Pharmaceuticals (PTPI), and Filament Health (FLHL). Unlike broad-market recreational cannabis producers, GCAN positions itself as a high-science biotech hybrid, focusing strictly on pharmaceutical-grade medical applications and non-invasive drug delivery technologies. The company is led by Chairman and CEO Aitan Zacharin, a seasoned executive with a background in technology and healthcare who has spearheaded the firm’s transition toward a biopharmaceutical-centric model. Zacharin also serves as the Acting CFO and Treasurer, maintaining a significant equity stake in the company. The scientific direction is guided by Chief Scientific Advisor Dr. Adi Aran, a world-renowned researcher in pediatric neurology and the lead investigator for the company’s clinical programs. The leadership team is further supported by Chief Operating Officer Motti Stenge. A cornerstone of the company’s strategic pedigree is its exclusive worldwide licensing agreement with Shaare Zedek Scientific Ltd., the research arm of one of Israel’s premier hospitals, which provides the foundational IP for its neuropsychiatric therapeutic pipeline.